A Randomized, Cross-over Study to Compare Quality of Life and Satisfaction in Primary Immunodeficient Patients Treated With Subcutaneous Injections of Gammanorm(R) 165 mg/mL According to the Delivery Device: Injections Using Pump or Rapid Push.
Phase of Trial: Phase IV
Latest Information Update: 16 Aug 2016
At a glance
- Drugs Immune globulin (Primary)
- Indications Immunodeficiency disorders
- Focus Therapeutic Use
- Sponsors Octapharma
- 12 Aug 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2017.
- 12 Aug 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2017.
- 21 Oct 2015 Planned End Date changed from 1 Oct 2015 to 1 Dec 2015 as reported by ClinicalTrials.gov